<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ900416-0068</DOCNO><DOCID>900416-0068.</DOCID><HL>   Genetics Institute Says   Loss Grew in Quarter</HL><DATE>04/16/90</DATE><SO>WALL STREET JOURNAL (J), PAGE B6F</SO><CO>   GENI</CO><IN>EARNINGS (ERN)</IN><LP>   CAMBRIDGE, Mass. -- Genetics Institute Inc. said itsfirst-quarter loss widened and revenue fell.   The biotechnology concern said the loss widened to $7million, or 57 cents a share, from $3.9 million, or 28 centsa share, a year earlier. Revenue fell 44% to $8.6 millionfrom $12.4 million.</LP><TEXT>   A spokeswoman said first-quarter results were hampered bylower shipments of the company's anemia drug, erythropoeitin,or EPO. She also said that the results didn't include anyrevenue from the manufacture or sale of an immunity-buildingprotein sold a year ago.</TEXT></DOC>